Tamea Sisco
evaluated for withdrawal symptoms over a ninety minute period. If the patient passed this test, they were given 50 mg Trexan®. The 1000 patients received the 50 mg. Trexan® daily until the patient relapsed. , . .
AMINO-ACID THERAPY
For this study twelve patients were selected, those selected received along with Trexan® a combination of amino acids. The number of days without a relapse or self-report of refusal to take either the Trexan® alone or in combination with the amino-acid formula was counted. Each patient (with some degree of failure) was evaluated on a daily basis either via phone or in a face-to-face contact.
COMMENT
Based on this research we suggest that the addition of the anti-craving formula significantly reduced the craving for opiates (possibly alcohol) and, therefore, seems to be important in assisting those hardcore opiate addicts in preventing relapse – especially in conjunction with the narcotic antagonist Trexan®. Naloxone binding was measured in frontal gray cortex, caudate nucleus, amygdala, hippocampus’ and cerebella cortex in human alcoholic and non-alcoholic subjects. Binding was found to be higher in alcoholics than in non-alcoholics for all of the brain regions examined. When subjects were grouped by the presence or absence of the DRD2AI allele, [3H] naloxone binding was lower in all brain regions examined of subjects with the A1 allele than in those without this allele, with a significant difference in the caudate nucleus. According to Ritchie and Noble (1996), these findings suggest one of the consequences of chronic alcohol exposure in humans is an enhancement of the brain opioid receptor system. However, the decreased [3H] naloxone binding with the A1 allele may be a compensatory response to their decreased dopaminergic modulation of opiate receptor activity.
Thus coupling amino-acid therapy and enkephalinase inhibition while blocking the delta receptors with a pure narcotic antagonist may be quite promising as a novel method to induce rapid detox in chronic methadone patients. This may also have important ramifications in the treatment of both opiate and alcohol dependent individuals, especially as a relapse prevention tool. It may also be interesting to further test this hypothesis with the sublingual combination of the partial opiate mu receptor agonist Buprenorphrine.
Tamea Sisco has been an Addictionologist in practice for over twelve years. Her facilities specialize in substance abuse rehabilitation through the implementation of Amino Acid therapy.
Article from articlesbase.com